Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
about
Oral pathology in inflammatory bowel diseaseIntestinal microbiota transplant - current state of knowledgeUse of biologics and chemotherapy in patients with inflammatory bowel diseases and cancerCytomegalovirus and ulcerative colitis: Place of antiviral therapyElderly patients and inflammatory bowel diseaseImmunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel diseasePharmacologic therapy for inflammatory bowel disease refractory to steroidsInfections and Chronic Inflammatory Bowel DiseaseWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel diseaseThe Role of Laboratory Tests in Crohn's DiseaseConcomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis: Case report and review of the literature.Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Healthcare maintenance in elderly patients with inflammatory bowel disease.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Approach to cytomegalovirus infections in patients with ulcerative colitis.Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.Hepatitis B vaccination in patients with inflammatory bowel disease.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Risk of infections associated with biological treatment in inflammatory bowel disease.The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy.Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease.Introducing vedolizumab to clinical practice: who, when, and how?Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.Review article: the practical management of acute severe ulcerative colitis.Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region.Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel diseaseCytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center studyCytomegalovirus in inflammatory bowel disease: A systematic review.Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences.Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home.Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn's ColitisSecond Korean guidelines for the management of ulcerative colitis.Variation in inflammatory bowel disease care among saudi pediatric gastroenterologists.Long-term safety of immunomodulators in pediatric inflammatory diseases.
P2860
Q26739055-8F3D529D-6E8B-4FD9-88EF-BB3936707FE6Q26741017-6AF3A8B9-02C1-4FCC-BF1E-371C055E543AQ26750190-847AA134-6E77-4F32-9CE3-0130DDBEE126Q26766101-6FBFAE20-577F-41B8-B998-3212EFE45F3FQ26768270-C5753E3D-722F-4832-B550-CB333FB4521CQ26777330-5D2B889D-AC4E-4E21-886D-532018FE0D8EQ26796415-F7B5DCD3-8A62-4CCB-B325-FA0E92EF057EQ26796518-361B2420-20A1-49E9-B08F-F57C778E0CB0Q27687191-D961855A-2CD2-48F3-BFDE-091F3D889875Q28073219-DA73BA6C-5A89-4455-AE1D-7F9B3ED2CAC7Q28075045-932F1EB0-A441-4958-A98B-E964FB9B2C87Q30244327-59A33EF9-C255-4385-85FF-FC84863EDFF3Q30244767-E03D15B1-8E35-4D81-AB4F-52057F96B376Q33621700-736926E7-AC2B-4D20-9BF2-82F550E4D526Q33654733-023BF0CA-F1E5-45A7-90F6-C189E9A664E6Q33690741-28A16D95-B086-4568-9DC6-ACDB618C8FB5Q33819473-4799DA49-CEA3-48F4-BB4D-AEBC8FA07C8FQ33819478-2BBA32C0-01A6-4E27-85F7-D3D69A5DFD5AQ33868659-29642386-E6C7-454B-B0CF-9F9CD006D53BQ34467285-B050BAD7-76B3-49C7-9B50-4B9E6749EFAFQ34528270-3FB5BCE0-01F0-4195-9BB1-ADDEB08D9F15Q34552028-492F1EFE-9162-43C7-81C9-A4EA37D3C60FQ35028459-23347B8C-6A0C-4FE9-8D32-5308AE11FC90Q35069514-3DFE0338-637A-4555-86F4-8AF5C4F0245BQ35199257-3E54BC23-45A6-42A0-91B9-DCC71AF3AA6BQ35271319-F9FD9982-4CDF-4F9D-8827-7696C0834696Q35562290-6DD312F4-DA10-4FD7-B646-889C22BAD71AQ35572174-8ED0FEAE-F0C4-49DD-BFEC-9A023D8C8390Q35883580-D4536888-0839-4283-8CA2-A2361A27D471Q35893859-969CE6C6-050F-4FDE-8A39-CB16A0477026Q36109460-7B8A869C-1A5A-4476-96C7-9A59678BC26AQ36193710-137C68EB-B15A-4AE8-96F5-B306D1904362Q36279017-1C6B854D-CC88-4AB0-9AE5-48B9FAEE75A6Q36471666-99C4BC75-2179-4E52-A6B2-E3F4245015ADQ36943693-A7E6AACA-ED4B-41B0-8D61-371A03F0C4FFQ37146476-840B2416-0D44-46F2-BB71-F5DDC1109266Q37249964-6136E107-7053-4C4F-B8FE-601D2D82E40CQ37662503-428B5F7A-F1A3-4F6D-9356-3AD2B14D114EQ37671228-8EBE347F-6923-47D3-89E4-29DDAD3D0314Q38232338-9B38C3BF-9A89-415B-AB47-5569C3DC2110
P2860
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Second European evidence-based ...... in inflammatory bowel disease.
@en
type
label
Second European evidence-based ...... in inflammatory bowel disease.
@en
prefLabel
Second European evidence-based ...... in inflammatory bowel disease.
@en
P2093
P50
P1476
Second European evidence-based ...... in inflammatory bowel disease
@en
P2093
E Macmahon
European Crohn's and Colitis Organisation (ECCO)
G Veereman-Wauters
J F Colombel
J F Rahier
K Katsanos
L Tremblay
L de Ridder
P304
P356
10.1016/J.CROHNS.2013.12.013
P577
2014-03-06T00:00:00Z